Gujarat Kidney And Super Speciality Limited has informed the Exchange about change in Management
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The company held a Board meeting on May 28, 2026, approving audited standalone and consolidated financial results for FY2026. Standalone net profit grew ~9% YoY to Rs 990.14 Lacs, while consolidated net profit surged ~77% YoY to Rs 1,681.18 Lacs driven by the acquisition of multiple subsidiaries. Total consolidated income reached Rs 8,288.60 Lacs, up from Rs 4,039.70 Lacs in the prior year. The company also raised equity capital of Rs 25,079.56 Lacs (net of share issue expenses of Rs 3,330.12 Lacs). Notably, the agenda for CEO appointment was deferred by the Board. New internal auditor (Mr Siddharth Atulbhai Shah) and secretarial auditor (SPANJ & Associates for five years) were appointed. A postal ballot is being conducted for shareholder approval on variation in objects of the IPO.
The strong consolidated financial growth and equity raise are positive, but the deferred CEO appointment could create uncertainty. The upcoming postal ballot on IPO object variation warrants monitoring as it may signal a change in capital deployment strategy.